rAd.sT enhanced the efficacy of concomitant anti-PD-1 and anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) treatment in an immunocompetent 4T1 breast cancer model [101]. This evidence concerns the gene CTLA4 and breast carcinoma.